This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.
Male patients aged from 18 to 75 years old;
The patients' ECOG score ≤ 2;
Previous new endocrine therapy is ineffective;
Past treatment with too much citabine or cabatase is ineffective.
Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.);
Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3/CD28 is insufficient (< 5 times);
The vital signs are abnormal and those who cannot cooperate with the inspectors;
Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation;
The Affiliated Hospital of Xuzhou Medical University
Lead sponsor
Xuzhou Medical University
Collaborator